Nadja Jäkel

9PUBLICATIONS
78CO-AUTHORS
Cardiovascular medicine and haematology not elsewhere classifiedImmunogenetics (incl. genetic immunology)Haematological tumoursNanomedicineHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 10, 2026
Does stringent cytoreduction improve survival in advanced proliferative chronic myelomonocytic leukemia?

Dorothée Selimoglu-Buet, Sylvie Chevret, Valeria Santini

|Aug 28, 2025
Long-Term Immune Response to SARS-CoV-2 Vaccination in Hematologic Malignancies: An Update of the ImV-HOng Trial of the East German Study Group for Hematology and Oncology.

Susann Schulze, Sabrina Jotschke, Robby Engelmann

|Aug 05, 2025
Association of the composition of the bone marrow tumor microenvironment in BCR::ABL1-negative myeloproliferative neoplasms with IFN-γ signaling and driver mutations.

Marcus Bauer, Christoforos Vaxevanis, Nadja Jaekel

|Mar 22, 2023
Vector-based SARS-CoV-2 vaccination is associated with improved T-cell responses in hematological neoplasia.

Robby Engelmann, Nadja Jaekel, Sabrina Jotschke

|Dec 01, 2022
Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.

Raphael Itzykson, Valeria Santini, Sylvain Thepot

|Mar 25, 2022
Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO).

Sabrina Jotschke, Susann Schulze, Nadja Jaekel

Pageof 2

Frequent Collaborators

4 joint publications

Haifa Kathrin Al-Ali

3 joint publications

Susann Schulze

3 joint publications

Beatrice Ludwig-Kraus

3 joint publications

Robby Engelmann